IJuniper Biologics imemezele namuhla ukuthi ithole amalungelo elayisensi yokuthuthukisa nokudayisa i-TG-C LD (i-TissueGene-C umthamo ophansi) yokwelapha i-knee osteoarthritis.
Isivumelwano selayisense esingu-$600 million USD esihlanganisa i-Asia Pacific, Middle East kanye ne-Afrika sisayinwe ne-Kolon Life Science futhi siwukutholwa kwesibili kukaJuniper Biologics ezinyangeni ezingaki. Ngaphansi kwemibandela yobambiswano, iJuniper Biologics izoba nesibopho sokuthuthukisa nokudayisa i-TG-C LD kochwepheshe bezokwelapha nezibhedlela ngaphakathi kwalezi zifunda. I-Kolon Life Science izoba nesibopho sokusekela intuthuko kanye nokuhlinzeka nge-TG-C LD.
I-TG-C LD iwukwelashwa kophenyo okungahlinzeki okuye kwatuswa njengokwelapha ngezakhi zofuzo zokuqala emhlabeni wonke ze-osteoarthritis of the knee,[i] okuwuhlobo oluvame kakhulu lwesifo samathambo.[ii] Ngokocwaningo, i-osteoarthritis kulinganiselwa ukuthi iyimbangela yeshumi nanye [1] ehamba phambili yokukhubazeka emhlabeni wonke ngeziguli ezilinganiselwa ezigidini ezingu-300 e-Asia Pacific naseMpumalanga Ephakathi nase-Afrika kuphela, ezihlushwa imiphumela ebuthaka yesifo esiwohlokayo samalunga. Ingenye yezidingo zezokwelapha ezinkulu kakhulu ezingahlangatshezwana nezimo ze-musculoskeletal nengozi eboniswa ukukhula ngeminyaka[iii].
Ukwelashwa kofuzo lweseli lokuqala esigabeni sokuqala, i-TG-C LD iqondise i-knee osteoarthritis ngomjovo owodwa we-intra-articular. U-Kolon TissueGene, umnikazi welayisensi ye-TG-C e-United States (hhayi i-TG-C LD), usevele uluqedile uhlolo lwesigaba sesi-2 lomtholampilo e-United States, ngedatha yokuqala ebonisa ukukhululeka kobuhlungu okuqhubekayo nokuthuthukiswa kokuhamba kulandela umjovo owodwa idolo elihlangene, mhlawumbe kuze kufike eminyakeni emi-2. Izivivinyo zomtholampilo zesigaba sesi-3 e-United States ezihlanganisa iziguli eziyi-1,020 ziyaqhubeka njengamanje ukuze kuqinisekiswe ukuphepha nokusebenza ngempumelelo kwe-TG-C. Ngaphezu kokuqinisekisa ukuncishiswa kobuhlungu okuphawulekayo kanye nokuthuthukiswa kokusebenza okuphawulwe kusukela kuhlolo lomtholampilo lweSigaba sesi-2 sase-US, izinhlolo ziklanyelwe ukukhombisa ukubambezeleka kokuqhubeka kwesifo ukuze kuzuzwe igama le-DMOAD (Isifo Esishintsha I-Osteoarthritis).
Isikhulu esiphezulu seJuniper Biologics, uRaman Singh, uthe: “Sihlale sibheka ukukhomba izindawo esingenza kuzo umehluko omkhulu futhi i-TG-C LD inikeza usizo olukhulu ezigulini zamadolo osteoarthritis ebezingadinga ukuhlinzwa noma ezinye izindlela zokwelapha. Sizibophezele ekuhlinzekeni ngemithi emisha yokwelapha i-osteoarthritis yamadolo ngokuvuselelwa kwe-cartilage futhi sikholelwa ukuthi lolu cwaningo lokwelapha olusha luzoletha impumuzo ezigidini zeziguli esifundeni sonke. "
“Sijabule ukusebenzisana neJuniper Biologics ukusungula izindlela ezintsha zeziguli ukuze zithole lolu hlelo olusha lokwelashwa kwamaseli. Lokhu kuzoba ukuqinisekiswa kobuchwepheshe bethu kanye nenani lemakethe,” kusho uMongameli weWoosok Lee kanye ne-CEO, i-Kolon Life Science. "Sikholelwa ukuthi iziguli zase-Asia Pacific, Middle East nase-Afrika zizokwazi ukuzuza ku-TG-C LD njengoba sidlula ebunzimeni bokuyisungula njengendlela yokwelapha ejwayelekile yomhlaba wonke."
